AbbVie Inc. (NYSE:ABBV)

Friday’s Top Analyst Upgrades and Downgrades: AbbVie, Bristol-Myers, Eli Lilly, First Solar, Generac, Oracle, Sirius XM, Southwest, Wendy’s and More

Stocks were looking for direction on Friday morning, after the Dow and S&P 500 broke to new all-time highs this week. The Dow now has hit close to 50 new highs since ...
Read Full Story »

Major Pharma Short Interest Surges

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Thursday’s Biggest Winners and Losers in the S&P 500

September 7, 2017: The S&P 500 closed flat at 2,465.16. The DJIA closed down 0.1% at 21,786.29. Separately, the Nasdaq closed relatively flat at 6,397.87. Thursday was a mixed day for ...
Read Full Story »

Short Sellers Run for Cover From Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Hike Bets in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

A blockbuster drug is about to get a chance to have even higher sales. The U.S. Food and Drug Administration (FDA) has expanded its approval of Imbruvica for the treatment ...
Read Full Story »

AbbVie Slips Despite Q2 Earnings Beat

AbbVie Inc. (NYSE: ABBV) reported its second-quarter financial results before the markets opened on Friday. The biotech giant posted $1.42 in earnings per share (EPS) and $6.94 billion in revenue, ...
Read Full Story »

Major Pharma Short Interest Takes a Big Step Back

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

Healthcare, which struggled mightily during the brutal election season last year and even back into 2015, has had a nice first half of 2017. Given the current nosebleed levels of ...
Read Full Story »

Major Pharma Short Sellers Become More Selective

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Run for Cover From Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Grow More Selective on Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

15 Companies Bracing for Big ASCO Reactions

This year marks the 53rd Annual Meeting for the American Society of Clinical Oncology (ASCO), where biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference (June ...
Read Full Story »

Top Presentations to Look for at ASCO

It almost the end of May, and that means one thing for biotech investors. The king of biotech and pharma events is about to take place. The 2017 annual meeting ...
Read Full Story »

Big Pharma Has Big Catalysts Coming for the Rest of 2017

The big pharmaceutical stocks are one area that has done somewhat better this year. One major reason for that is the shrill rhetoric from politicians has quieted as the election ...
Read Full Story »